Human tumor-induced and naturally occurring Treg cells differentially affect NK cells activated by either IL-2 or target cells

European Journal of Immunology

Volumn 41, Issue 12, 2011, Pages 3564-3573

  Bergmann, Christoph ^a   Wild, Clarissa A ^a   Narwan, Mustafa ^a   Lotfi, Ramin ^b   Lang, Stephan ^a   Brandau, Sven ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Head and neck cancer; Induced regulatory T cells; NK cell; Perforin

Indexed keywords

FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL KILLER CELL RECEPTOR NKG2D; PERFORIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL ACTIVATION; CYTOLYSIS; DEGRANULATION; HUMAN; HUMAN CELL; IN VIVO STUDY; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TARGET CELL; TUMOR MICROENVIRONMENT;

ANTIGENS, CD; CELL LINE, TUMOR; CELLS, CULTURED; FAS LIGAND PROTEIN; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; K562 CELLS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PERFORIN; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 82255164203     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201141532     Document Type: Article

References (45)

1. Roncarolo, M. G., Gregori, S., Battaglia, M., Bacchetta, R., Fleischhauer, K. and Levings, M. K., Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 2006. 212: 28-50.
2. Groux, H., Type 1 T-regulatory cells: their role in the control of immune responses. Transplantation 2003. 75: 8S-12S.
3. Strauss, L., Bergmann, C., Szczepanski, M., Gooding, W., Johnson, J. T. and Whiteside, T. L., A unique subset of CD4+CD25highFoxp3+T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin. Cancer Res. 2007. 13: 4345-4354.
4. Bergmann, C., Strauss, L., Wang, Y., Szczepanski, M. J., Lang, S., Johnson, J. T. and Whiteside, T. L., T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin. Cancer Res. 2008. 14: 3706-3715.
5. Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M. et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004. 10: 942-949.
6. Trinchieri, G., Natural killer cells wear different hats: effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis. Semin. Immunol. 1995. 7: 83-88.
7. Screpanti, V., Wallin, R. P., Grandien, A. and Ljunggren, H. G., Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells. Mol. Immunol. 2005. 42: 495-499.
8. Moretta, L. and Moretta, A., Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J. 2004. 23: 255-259.
9. Biassoni, R., Cantoni, C., Marras, D., Giron-Michel, J., Falco, M., Moretta, L. and Dimasi, N., Human natural killer cell receptors: insights into their molecular function and structure. J. Cell Mol. Med. 2003. 7: 376-387.
10. Wu, J. D., Higgins, L. M., Steinle, A., Cosman, D., Haugk, K. and Plymate, S. R., Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J. Clin. Invest. 2004. 114: 560-568.
11. Ghiringhelli, F., Menard, C., Terme, M., Flament, C., Taieb, J., Chaput, N., Puig, P. E. et al., CD4+CD25+regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med. 2005. 202: 1075-1085.
12. Smyth, M. J., Teng, M. W., Swann, J., Kyparissoudis, K., Godfrey, D. I. and Hayakawa, Y., CD4+CD25+T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 2006. 176: 1582-1587.
13. Bergmann, C., Strauss, L., Zeidler, R., Lang, S. and Whiteside, T. L., Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment. Cancer Immunol. Immunother. 2007. 56: 1429-1442.
14. Battaglia, M., Stabilini, A., Migliavacca, B., Horejs-Hoeck, J., Kaupper, T. and Roncarolo, M. G., Rapamycin promotes expansion of functional CD4+CD25+FOXP3+regulatory T cells of both healthy subjects and type 1 diabetic patients. J. Immunol. 2006. 177: 8338-8347.
15. Groux, H., O'Garra, A., Bigler, M., Rouleau, M., Antonenko, S., de Vries, J. E. and Roncarolo, M. G., A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997. 389: 737-742.
16. Astier, A. L., Meiffren, G., Freeman, S. and Hafler, D. A., Alterations in CD46-mediated Tr1 regulatory T cells in patients with multiple sclerosis. J. Clin. Invest. 2006. 116: 3252-3257.
17. Raulet, D. H., Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 2003. 3: 781-790.
18. Raulet, D. H. and Guerra, N., Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat. Rev. Immunol. 2009. 9: 568-580.
19. Zhou, H., Chen, L., You, Y., Zou, L. and Zou, P., Foxp3-transduced polyclonal regulatory T cells suppress NK cell functions in a TGF-beta dependent manner. Autoimmunity 2010. 43: 299-307.
20. Meadows, S. K., Eriksson, M., Barber, A. and Sentman, C. L., Human NK cell IFN-gamma production is regulated by endogenous TGF-beta. Int. Immunopharmacol. 2006. 6: 1020-1028.
21. Konjevic, G., Mirjacic Martinovic, K., Vuletic, A. and Babovic, N., In-vitro IL-2 or IFN-alpha-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients. Melanoma Res. 2010. 20: 459-467.
22. Forte, P., Lilienfeld, B. G., Baumann, B. C. and Seebach, J. D., Human NK cytotoxicity against porcine cells is triggered by NKp44 and NKG2D. J. Immunol. 2005. 175: 5463-5470.
23. Frimpong-Boateng, K., van Rooijen, N. and Geiben-Lynn, R., Regulatory T cells suppress natural killer cells during plasmid DNA vaccination in mice, blunting the CD8+T cell immune response by the cytokine TGF-beta. PLoS One 2010. 5: e12281.
24. Giroux, M., Yurchenko, E., St-Pierre, J., Piccirillo, C. A. and Perreault, C., T regulatory cells control numbers of NK cells and CD8alpha+immature dendritic cells in the lymph node paracortex. J. Immunol. 2007. 179: 4492-4502.
25. Ralainirina, N., Poli, A., Michel, T., Poos, L., Andres, E., Hentges, F. and Zimmer, J., Control of NK cell functions by CD4+CD25+regulatory T cells. J. Leukoc. Biol. 2007. 81: 144-153.
26. Barao, I., Hanash, A. M., Hallett, W., Welniak, L. A., Sun, K., Redelman, D., Blazar, B. R. et al., Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+regulatory T cells. Proc. Natl. Acad. Sci. USA 2006. 103: 5460-5465.
27. Shimizu, J., Yamazaki, S. and Sakaguchi, S., Induction of tumor immunity by removing CD25+CD4+T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 1999. 163: 5211-5218.
28. Herberman, R. B., Cancer immunotherapy with natural killer cells. Semin. Oncol. 2002. 29: 27-30.
29. Badoual, C., Hans, S., Rodriguez, J., Peyrard, S., Klein, C., Agueznay Nel, H., Mosseri, V. et al., Prognostic value of tumor-infiltrating CD4+T-cell subpopulations in head and neck cancers. Clin. Cancer Res. 2006. 12: 465-472.
30. Correale, P., Rotundo, M. S., Del Vecchio, M. T., Remondo, C., Migali, C., Ginanneschi, C., Tsang, K. Y. et al., Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J. Immunother. 2010. 33: 435-441.
31. Carreras, J., Lopez-Guillermo, A., Fox, B. C., Colomo, L., Martinez, A., Roncador, G., Montserrat, E. et al., High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006. 108: 2957-2964.
32. Alvaro, T., Lejeune, M., Salvado, M. T., Bosch, R., Garcia, J. F., Jaen, J., Banham, A. H. et al., Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin. Cancer Res. 2005. 11: 1467-1473.
33. Salama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., Joseph, D., Platell, C. and Iacopetta, B., Tumor-infiltrating FOXP3+T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 2009. 27: 186-192.
34. Nishikawa, H. and Sakaguchi, S., Regulatory T cells in tumor immunity. Int. J. Cancer 2010. 127: 759-767.
35. Dannull, J., Su, Z., Rizzieri, D., Yang, B. K., Coleman, D., Yancey, D., Zhang, A. et al., Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 2005. 115: 3623-3633.
36. Berntsen, A., Brimnes, M. K., thor Straten, P. and Svane, I. M., Increase of circulating CD4+CD25highFoxp3+regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2. J. Immunother. 2010. 33: 425-434.
37. Jacobs, J. F., Punt, C. J., Lesterhuis, W. J., Sutmuller, R. P., Brouwer, H. M., Scharenborg, N. M., Klasen, I. S. et al., Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients. Clin. Cancer Res. 2010. 16: 5067-5078.
38. Zimmer, J., Andres, E. and Hentges, F., NK cells and Treg cells: a fascinating dance cheek to cheek. Eur. J. Immunol. 2008. 38: 2942-2945.
39. Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J. H., Lanier, L. L. and Spies, T., Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999. 285: 727-729.
40. Roy, S., Barnes, P. F., Garg, A., Wu, S., Cosman, D. and Vankayalapati, R., NK cells lyse T regulatory cells that expand in response to an intracellular pathogen. J. Immunol. 2008. 180: 1729-1736.
41. Cao, X., Cai, S. F., Fehniger, T. A., Song, J., Collins, L. I., Piwnica-Worms, D. R. and Ley, T. J., Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007. 27: 635-646.
42. Vacca, P., Cantoni, C., Vitale, M., Prato, C., Canegallo, F., Fenoglio, D., Ragni, N. et al., Crosstalk between decidual NK and CD14+myelomonocytic cells results in induction of Tregs and immunosuppression. Proc. Natl. Acad. Sci. USA 2010. 107: 11918-11923.
43. Heo, D. S., Snyderman, C., Gollin, S. M., Pan, S., Walker, E., Deka, R., Barnes, E. L. et al., Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines. Cancer Res. 1989. 49: 5167-5175.
44. Busche, A., Goldmann, T., Naumann, U., Steinle, A. and Brandau, S., Natural killer cell-mediated rejection of experimental human lung cancer by genetic overexpression of major histocompatibility complex class I chain-related gene A. Hum. Gene Ther. 2006. 17: 135-146.
45. Aktas, E., Kucuksezer, U. C., Bilgic, S., Erten, G. and Deniz, G., Relationship between CD107a expression and cytotoxic activity. Cell Immunol. 2009. 254: 149-154.